Table 1.
Patient demographics and clinical characteristics.
| Clinical variable | Disease-controlled patient | Disease-progressed patient | P value |
|---|---|---|---|
| n = 12 | n = 18 | ||
| Age (years): median 67 years old | |||
| < 67 | 6 | 9 | > 0.9999 |
| ≥ 67 | 6 | 9 | |
| Sex | |||
| Male | 12 | 14 | 0.1297 |
| Female | 0 | 4 | |
| Primary site | |||
| Paranasal sinus | 1 | 4 | 0.3884 |
| Oral cavity | 2 | 1 | |
| Nasopharynx | 0 | 2 | |
| Oropharynx | 1 | 4 | |
| Hypopharynx | 7 | 5 | |
| Larynx | 1 | 1 | |
| Parotid gland | 0 | 1 | |
| Local recurrence | |||
| (−) | 7 | 8 | 0.7104 |
| (+) | 5 | 10 | |
| Lymph node metastasis | |||
| (−) | 7 | 8 | 0.7104 |
| (+) | 5 | 10 | |
| Distant metastasis | |||
| (−) | 5 | 8 | > 0.9999 |
| (+) | 7 | 10 | |
| Performance status | |||
| 0 | 10 | 9 | 0.1213 |
| 1 | 2 | 9 | |
| Previous radiotherapy | |||
| (−) | 3 | 3 | 0.6599 |
| (+) | 9 | 15 | |
| PD-L1 expression | |||
| < 1% | 3 | 10 | 0.4197 |
| ≥ 1% | 6 | 8 | |
| Unevaluable | 3 | 0 | |
| Nivolumab treatment | |||
| < 4 times | 3 | 5 | > 0.9999 |
| ≥ 4 times | 9 | 13 | |